Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-X(L)–Specific Degrader DT2216

Pancreatic cancer is the third most common cause of cancer-related deaths in the United States. Although gemcitabine is the standard of care for most patients with pancreatic cancer, its efficacy is limited by the development of resistance. This resistance may be attributable to the evasion of apopt...

Descripción completa

Detalles Bibliográficos
Autores principales: Thummuri, Dinesh, Khan, Sajid, Underwood, Patrick W., Zhang, Peiyi, Wiegand, Janet, Zhang, Xuan, Budamagunta, Vivekananda, Sobh, Amin, Tagmount, Abderrahmane, Loguinov, Alexander, Riner, Andrea N., Akki, Ashwin S., Williamson, Elizabeth, Hromas, Robert, Vulpe, Christopher D., Zheng, Guangrong, Trevino, Jose G., Zhou, Daohong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Targeting Drug Resistance
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742767/
https://www.ncbi.nlm.nih.gov/pubmed/34667112
http://dx.doi.org/10.1158/1535-7163.MCT-21-0474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742767/
https://www.ncbi.nlm.nih.gov/pubmed/34667112
http://dx.doi.org/10.1158/1535-7163.MCT-21-0474

Ejemplares similares